Amoneta Diagnostics at AD/PD™ 2025: APO-Easy® Genotyping kit in the Context of New Therapies’ Launch
Amoneta Diagnostics is pleased to announce its’ team’s participation to the AD/PD™ 2025 conference, a major international ev...
On November 28th, our CEO, Dr. Stéphanie Boutillier, was honored to speak at “Meet&Match”, a networking event hosted by B...
We are excited to announce that our team will not only be attending but also presenting at the 2024 Clinical Trials on Alzheimer's...
Amoneta announces the CE-marking under the EU-IVDR of its APO-Easy® Genotyping Kit.
Amoneta Diagnostics' innovative diagnostic tools are now available on the MedicalExpo platform